Literature DB >> 9349415

Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome.

N A Rao1.   

Abstract

Although the inciting events in the pathogenesis of sympathetic ophthalmia and Vogt-Koyanagi-Harada (VKH) syndrome are different, these two forms of bilateral, granulomatous uveitis share several clinical, histopathological and immunohistochemical features, including their association with HLA types and in their in vitro T-cell response to retinal antigens. These clinical and immunopathological features indicate that there is an underlying T-cell mediated autoimmunity to uveal/retinal antigens in the development of these forms of uveitis. Both forms exhibit preservation of the choriocapillaris and retina despite extensive inflammatory cell infiltration in the choroid. Recent experimental studies suggest that this preservation of choriocapillaris could be the result of anti-inflammatory products secreted by the retinal pigment epithelium, including transforming growth factor-beta and a novel protein called retinal pigment epithelial protective protein that is known to suppress the phagocyte generation of superoxide. Such suppression of the oxidant release in the choroidal inflammation could help protect the uvea from necrotic change and preserve the choriocapillaris from inflammatory cell infiltration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349415     DOI: 10.1038/eye.1997.54

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  25 in total

Review 1.  Sympathetic ophthalmia: an autoimmune ocular inflammatory disease.

Authors:  C C Chan; M Mochizuki
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

3.  MR imaging of Vogt-Koyanagi-Harada syndrome with leptomeningeal enhancement.

Authors:  B D Lohman; C A Gustafson; A M McKinney; B Sarikaya; S C Silbert
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-04       Impact factor: 3.825

4.  The positive role of lumbar puncture in the diagnosis of Vogt-Koyanagi-Harada disease: lymphocyte subsets in the aqueous humor and cerebrospinal fluid.

Authors:  Nobuyoshi Kitaichi; Hiroko Matoba; Shigeaki Ohno
Journal:  Int Ophthalmol       Date:  2007-01-09       Impact factor: 2.031

Review 5.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

6.  Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings.

Authors:  Daniel V Vasconcelos-Santos; Elliott H Sohn; Srinivas Sadda; Narsing A Rao
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

7.  A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients.

Authors:  Jean-Marie Tiercy; Sivakumar R Rathinam; Marianne Gex-Fabry; Edoardo Baglivo
Journal:  Mol Vis       Date:  2010-03-05       Impact factor: 2.367

8.  Increased frequency of anti-retina antibodies in asymptomatic patients with chronic t. gondii infection.

Authors:  Sylvia Regina Temer Cursino; Thaís Boccia da Costa; Joyce Hisae Yamamoto; Luciana Regina Meireles; Maria Antonieta Longo Galvão Silva; Heitor Franco de Andrade Junior
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Trabecular meshwork depigmentation in Vogt-Koyanagi-Harada disease.

Authors:  Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Kenichi Namba; Yukihiro Horie; Susumu Ishida; Shigeaki Ohno
Journal:  Jpn J Ophthalmol       Date:  2013-01-29       Impact factor: 2.447

Review 10.  Sympathetic ophthalmia.

Authors:  Claudia Patricia Castiblanco; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.